Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvsef crawled date : 2022 - 06 - 06 save search
Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight
Published: 2022-06-06 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
OMER | $3.085 1.15% 1.13% 280K
|
Health Technology
|
| O: 0.8%
H: 2.78%
C: -13.1%
lupus market
Third Harmonic Bio Appoints Edward R. Conner, M.D., as Chief Medical Officer
Published: 2022-06-06 (Crawled : 13:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
Published: 2022-06-06 (Crawled : 12:20) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
tafinlar novartis
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.